Astellas, KMPH, SRNE To Face FDA, ALXN Trims Workforce, ALDX Soars On Trial Data

Today's Daily Dose brings you news about regulatory catalysts awaiting Astellas, KemPharm and Sorrento; Aldeyra's positive phase IIa clinical trial results in dry eye disease; Inotek's merger with Rocket Pharmaceuticals and Zafgen's progress in phase II trial of ZGN-1061 in type 2 diabetes.

from RTT - Biotech http://ift.tt/2fgMEOj
via IFTTT